Clinical Trials
15 trialsNCT06696846 2026-04-30
CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Recruiting
NCT03829540 2026-04-27
CD4CAR for CD4+ Leukemia and Lymphoma
Indiana University
Phase 1 Recruiting
NCT05984147 2026-04-17
ASHA-1
Aurigene Discovery Technologies Limited
Phase 1 Recruiting
NCT03017820 2026-04-13
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Phase 1 Recruiting
NCT06508463 2026-04-13
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Mayo Clinic
Phase 1 Recruiting
NCT05010005 2026-04-09
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT07382817 2026-02-27
Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05079282 2026-02-13
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Ono Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06934382 2025-12-26
24CT015
Children's Hospital of Philadelphia
Phase 1 Recruiting
NCT06420089 2025-11-10
VIPER101
Vittoria Biotherapeutics
Phase 1 Recruiting
NCT06712810 2025-10-10
Q702 for the Treatment of Patients With Hematologic Malignancies
Mayo Clinic
Phase 1 Recruiting
NCT04234048 2025-09-22
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
SciTech Development, Inc.
Phase 1 Recruiting
NCT06547528 2025-06-03
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
Ono Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06699771 2025-04-30
Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies
GC Cell Corporation
Phase 1 Recruiting
NCT05476770 2024-12-06
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Recruiting